Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

    Recruiting

    3 1 1
    Investigated Drugs:
    Belgium France Italy Spain
  • Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Czechia Denmark France Germany Italy The Netherlands +3
  • Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

    Recruiting

    2 1 1 1
    Belgium France Germany Italy The Netherlands Spain
  • Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    1 1 1 1
    Belgium Italy The Netherlands Poland Spain Sweden
  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Spain
  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Belgium Denmark France Germany Greece Hungary +6
  • Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

    Not yet recruiting

    2 1 1 1
    Germany Italy
  • Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

    Not yet recruiting

    2 1 1
    France Germany Italy Spain
  • Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    France Spain
  • A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Poland +1